Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide vs Dupilumab in Eosinophilic Esophagitis
NCT07358234Phase 1Enrolling by invitation
- Sponsor
- Mayo Clinic
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1 trial of dupilumab in eosinophilic esophagitis (EoE) (2 arms), sponsored by Mayo Clinic. Primary endpoint: Esophageal diameter at 14 weeks. Started Feb 2026; status: enrolling by invitation.
02
Drugs
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT07358234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07358234.